CHRS Coherus Oncology, Inc.
Price Chart
Executive Summary
Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14.3M estimate by 14.0%. LOQTORZI revenue grew 61% YoY to $11.8M, but total revenue was dragged lower than expected, and the company completed a dilutive $53.6M equity offering during the quarter.
Key Financial Metrics
Actionable Insight
The EPS beat is overshadowed by a clear revenue miss and heavy dilution from the Q1 offering. Watch for mid-2026 pipeline data readouts (casdozokitug, tagmokitug) as key catalysts; the $167M cash position provides runway but operating burn remains high at ~$58M/quarter.
Key Facts
- GAAP EPS from continuing operations: -$0.27 vs consensus -$0.29 (beat by 6.9%)
- Revenue: $12.3M vs consensus $14.3M (miss by 14.0%)
- LOQTORZI net product revenue: $11.8M, up 61% YoY from $7.3M
- Net loss from continuing operations improved to -$36.9M from -$47.4M YoY
- Cash, equivalents and marketable securities: $167.0M at quarter-end
- Completed public offering of 32.89M shares for net proceeds of $53.6M in Q1 2026
- Operating cash flow: -$57.9M in Q1 2026 vs -$25.8M in Q1 2025
- Pipeline catalysts: casdozokitug Phase 2 1L HCC data expected mid-2026; tagmokitug multiple readouts in 2026
Financial Impact
Revenue miss of $2.0M (14%) vs consensus; EPS beat of $0.02 (6.9%); $53.6M dilutive equity offering increased share count by ~31%
Risk Factors
- Revenue miss of 14% vs consensus signals weaker-than-expected LOQTORZI adoption
- Dilution of ~31% from Q1 equity offering pressures per-share metrics
- Operating cash burn of -$57.9M in Q1 2026, up from -$25.8M YoY
- Heavy reliance on pipeline data readouts for valuation inflection
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292299 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
DEFA14A
| $1.65 $1.58 | ▼ −4.55% | ▼ −4.86% | $1.42 (−13.94%) |
|
May 11, 2026
29d ago
|
Press Release
| $1.71 $1.49 | ▼ −12.87% | ▼ −12.94% | $1.42 (−16.96%) |
|
May 5, 2026
5w ago
|
DEFA14A
| $1.75 $1.71 | ▼ −2.29% | ▼ −3.42% | $1.42 (−18.86%) |
|
May 4, 2026
5w ago
|
Press Release
| $1.73 $1.95 | ▲ +12.72% | ▲ +9.78% | $1.42 (−17.92%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $1.95 $1.68 | ▼ −13.85% | ▼ −12.94% | $1.42 (−27.18%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $1.65 $1.93 | ▲ +16.97% | ▲ +18.18% | $1.42 (−13.94%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $1.65 $1.93 | ▲ +16.97% | ▲ +18.18% | $1.42 (−13.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access